VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Official Title

A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - low grade B cell lymphoma - 1 or more sites of disease appropriate for intratumoral injection - measurable disease other than the injection site - Performance Status of 1 or better - Adequate bone marrow, renal and hepatic function - No active autoimmune disease or systemic immunosuppressive drugs - Life expectancy > 4 months
Exclusion Criteria:
  1. - Known HIV - Known brain metastases - Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK) - Anticoagulation therapy other than 325mg QD ASA - Significant cardiovascular disease - Pregnant or nursing


Ash A. Alizadeh, MD/PhD
Ash A. Alizadeh, MD/PhD
Medical oncologist, Lymphoma specialist, Cancer geneticist
Moghadam Family Professor
Manali Patel
Manali Patel
Medical oncologist
Associate Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.


Lori Richards